Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-12-02

Clinical Trial Update: A Factor IX Gene Therapy Study (FIX-GT) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial of a Factor IX gene therapy (FIX-GT) for Hemophilia B was terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FIX-GT (Factor IX gene therapy)

Snippet

Sponsor: University College, London | Conditions: Hemophilia B | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-12-02